InvestorsHub Logo

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
saturn_five Free
11/05/20 8:26 PM
profile icon
kpisme Free
08/28/20 2:18 PM
profile icon
geenback Free
08/27/20 12:44 PM
profile icon
ClayTrader Free
02/12/20 6:18 PM
profile icon
ttubular Free
02/11/20 6:14 PM
profile icon
ClayTrader Free
02/11/20 5:42 PM
profile icon
TheFinalCD PremiumMember
02/11/20 12:15 PM
profile icon
ttubular Free
02/11/20 11:50 AM
profile icon
wesley_ PremiumMember
02/11/20 10:58 AM
profile icon
ttubular Free
02/10/20 11:09 PM
profile icon
ttubular Free
02/10/20 5:39 PM
profile icon
ClayTrader Free
11/01/19 4:09 PM
profile icon
Crozz Free
06/19/19 2:51 PM
profile icon
Crozz Free
06/19/19 2:42 PM
profile icon
Crozz Free
06/19/19 2:37 PM
profile icon
Crozz Free
06/19/19 2:30 PM
profile icon
whytestocks Free
04/17/19 8:31 AM
profile icon
DorianGray Free
04/16/19 11:25 PM
profile icon
ClayTrader Free
04/16/19 4:53 PM
profile icon
UP Trend Free
04/16/19 10:06 AM
profile icon
whytestocks Free
04/16/19 10:00 AM
profile icon
Mistr Tommy Free
04/16/19 9:59 AM
profile icon
ttubular Free
04/16/19 9:53 AM
profile icon
airahim Free
04/16/19 9:09 AM
profile icon
Mistr Tommy Free
04/16/19 9:06 AM
profile icon
QuidRunner Free
04/16/19 8:57 AM
profile icon
crudeoil24 PremiumMember
04/16/19 8:56 AM
profile icon
QuidRunner Free
04/16/19 8:54 AM
profile icon
crudeoil24 PremiumMember
04/16/19 8:28 AM
profile icon
kpisme Free
04/11/19 4:12 PM
profile icon
ttubular Free
04/11/19 12:29 PM
profile icon
ttubular Free
04/10/19 4:24 PM
profile icon
PennyWorld PremiumMember
02/19/19 6:05 PM
profile icon
Crozz Free
02/19/19 3:04 PM
profile icon
PennyWorld PremiumMember
02/15/19 2:46 PM
profile icon
HSTN Free
02/15/19 2:42 PM
profile icon
PennyWorld PremiumMember
02/11/19 3:26 PM
profile icon
Crozz Free
02/11/19 12:00 PM
profile icon
PennyWorld PremiumMember
02/08/19 5:48 PM
profile icon
Crozz Free
02/08/19 12:11 PM
profile icon
Crozz Free
02/08/19 11:49 AM
profile icon
kpisme Free
02/07/19 5:46 PM
profile icon
Crozz Free
02/07/19 3:39 PM
profile icon
Crozz Free
02/07/19 3:35 PM
profile icon
Crozz Free
02/07/19 3:31 PM
profile icon
Crozz Free
02/07/19 3:28 PM
profile icon
420man Free
02/04/19 8:38 AM

Rexahn Pharmaceuticals, Inc. (REXN) RSS Feed

Followers
194
Posters
520
Posts (Today)
0
Posts (Total)
3898
Created
06/17/08
Type
Free
Moderators



   
 



   http://www.rexahn.com/cms/    

    http://finance.yahoo.com/q/ks?s=RNN

       

About

Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN) is a clinical stage biopharmaceutical company focused on developing best-in-class therapeutics for the treatment of cancer. Rexahn’s clinical development programs directly target specific proteins that are selectively expressed in human cancer cells, resulting in increased efficacy and reduced toxicity. In preclinical studies these drug candidates are effective against multiple drug resistant cancers and have shown to increase the effectiveness of various FDA approved cancer treatments. Rexahn is also developing specific biomarker tests that will help identify which patients will be most responsive to its treatments. The Company’s nanotechnology-based drug delivery system has shown it can make FDA approved chemotherapy drugs more effective.

Our clinical development pipeline consists of three novel compounds:

RX-3117 is a novel, oral, small molecule nucleoside compound.  Once intracellularly activated (phosphorylated) by the enzyme UCK2, it is incorporated into the DNA or RNA of cells and inhibits both DNA and RNA synthesis, which induces apoptotic cell death of tumor cells.  Because UCK2 is overexpressed in multiple human tumors, but has a very limited presence in normal tissues, RX-3117 offers the potential for a targeted anti-cancer therapy with an improved efficacy and safety profile, and we believe it has therapeutic potential in a broad range of cancers, including pancreatic, bladder, colon, and lung cancer.  RX-3117 has received “orphan drug designation” from the U.S. Food and Drug Administration (“FDA”) and from the European Commission (“EC”) for pancreatic cancer.

RX-5902 (Supinoxin™) is a potential first-in-class small molecule inhibitor of phosphorylated-p68, a protein that we believe plays a key role in cancer cell growth, progression and metastasis through its interaction with beta-catenin.  Phosphorylated p68, which is highly expressed in cancer cells, but not in normal cells, results in up-regulation of cancer-related genes and a subsequent proliferation of cancer cells and tumor growth.  RX-5902 selectively blocks the interaction of phosphorylated p68 with beta-catenin, thereby decreasing the proliferation or growth of cancer cells in preclinical models.  In addition, multiple pre-clinical models suggest that RX-5902 enhances the efficacy of immunotherapy. We have evaluated RX-5902 in a Phase 1 dose escalation study in patients with a diverse range of metastatic, treatment-refractory tumors, including breast, ovarian, colorectal, and neuro-endocrine tumors.  In February 2017, we initiated a Phase 2a clinical study of RX-5902 in patients with metastatic triple negative breast cancer (“TNBC”).

RX-0201 (Archexin®) is a potential best-in-class, potent inhibitor of the protein kinase Akt-1, which we believe plays a critical role in cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance.  RX-0201 is the subject of a research and development collaboration with Zhejiang Haichang Biotechnology Co., Ltd. (“Haichang”) for the development of RX-0201 for hepatocellular carcinoma. RX-0201 has received orphan drug designation from the FDA for renal cell carcinoma (“RCC”), glioblastoma, ovarian cancer, stomach cancer and pancreatic cancer.

These clinical development programs are part of a growing oncology drug pipeline that consists of highly differentiated and exciting anti-cancer compounds.

Our strategy is to continue building a significant clinical development pipeline of innovative therapies that we will commercialize on our own or with other pharmaceutical partners. Rexahn’s powerful discovery engine and differentiated product pipeline provide the opportunity for a high value generating biopharmaceutical company.

 

 Rexahn  Pipeline

Management Team



Peter Suzdak, Ph.D.
Chief Executive Officer 

Dr. Peter Suzdak joined Rexahn Pharmaceuticals in February 2013. Dr. Suzdak has over 25 years of diverse experience, including several management positions, in the pharmaceutical industry. Most recently, Dr. Suzdak was Chief Scientific Officer of Corridor Pharmaceuticals, a company developing small molecule compounds to treat pulmonary and vascular disorders. Prior to Corridor Pharmacueitcals, he was co-Founder, Chief Executive Officer and Chief Scientific Officer of Cardioxyl Pharmaceuticals, a company focused on therapies for the treatment of cardiovascular disease. Previous to Cardioxyl Pharmaceuticals, he was President and Chief Executive Officer of Artesian Therapeutics, a company engaged in the development of small molecule therapeutics for cardiovascular diseases. Dr. Suzdak’s experience also includes his position as Senior Vice President of Research and Development of Guilford Pharmaceuticals, a company that developed therapeutics and diagnostics for neurological diseases and cancer, and as Director of Neurobiology for Novo Nordisk. Dr. Suzdak holds a Ph.D. in pharmacology and toxicology from the University of Connecticut.

Rick Soni, MBA
President and Chief Operating Officer

Rick Soni joined Rexahn in 2008 with over 20 years of sales, marketing, product planning and business development experience in the pharmaceutical industry. Prior to joining Rexahn, Mr. Soni held leadership roles at Otsuka America Pharmaceuticals, Inc., with responsibility for commercial development, corporate strategy and execution of licensing and acquisition of therapeutics, diagnostics and medical devices. Previously, Mr. Soni has held a variety of management positions at Novartis and Schering-Plough. Mr. Soni has a BS from the University of Wisconsin-Madison and an MBA from Fairleigh Dickinson University.

Tae Heum (Ted) Jeong, D. Mgt.
Sr. Vice President  and Chief Financial Officer

Dr. Jeong has been Chief Financial Officer of Rexahn Pharmaceuticals since 2002. He oversees all aspects of capital raising, accounting, operations, and corporate development for Rexahn. He is also responsible for investor relations, and played a key role in Rexahn’s 2008 listing on the New York Stock Exchange (NYSE) AMEX. For the past 16 years, he has extensive experience in venture capital and investment banking industry that includes role at Hyundai Venture Investment Corporation where he managed the Biotechnology investment team. Dr. Jeong holds a Doctor of Management from University of Maryland and an M.S. in Finance from Johns Hopkins University




ANALYST COVERAGE
 
Roth Capital Partners, LLC
      Joseph Pantginis, Ph.D.
646-358-1907

jpantginis@roth.com

Maxim Group, LLC
Echo He, MD, Ph.D.
212-895-3718

ehe@maximgrp.com

H. C. Wainwright & Co., LLC
Andrew Fein
212-356-0546

afein@hcwco.com   


INVESTOR RELATIONSThe Trout Group LLC
Tricia Truehart
(646) 378-2953
ttruehart@troutgroup.com

Volume:
Day Range:
Last Trade Time:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
REXN Latest News
  • No Recent News Available for this company!
New Post